Sygnis SA (WSE:SYG)
Poland · Delayed Price · Currency is PLN 2.600
+0.020 (0.78%)
At close: Oct 10, 2025
Sygnis Revenue
Sygnis had revenue of 3.39M PLN in the quarter ending June 30, 2025, with 22.87% growth. This brings the company's revenue in the last twelve months to 15.41M, down -8.19% year-over-year. In the year 2023, Sygnis had annual revenue of 20.03M, down -29.73%.
Revenue (ttm)
15.41M
Revenue Growth
-8.19%
P/S Ratio
4.34
Revenue / Employee
n/a
Employees
46
Market Cap
66.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 20.03M | -8.48M | -29.73% |
| Dec 31, 2022 | 28.51M | 25.11M | 739.70% |
| Dec 31, 2021 | 3.39M | 600.08K | 21.47% |
| Dec 31, 2020 | 2.79M | 509.95K | 22.32% |
| Dec 31, 2019 | 2.28M | -236.14K | -9.37% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Diagnostyka | 2.17B |
| NEUCA | 13.04B |
| Synektik Spólka Akcyjna | 623.20M |
| Voxel | 560.38M |
| Celon Pharma | 206.22M |
| Selvita | 373.90M |
| Centrum Medyczne ENEL-MED | 789.78M |
| Ryvu Therapeutics | 130.10M |